MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, EDIT made $2,831K in revenue. -$24,982K in net income. Net profit margin of -882.44%.

Income Overview

Revenue
$2,831K
Net Income
-$24,982K
Net Profit Margin
-882.44%
EPS
-$0.26
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Collaboration and other research and development revenues
2,831 24,741 7,543 3,578
Research and development
17,600 27,404 19,775 16,181
General and administrative
10,234 11,353 12,316 12,859
Restructuring and impairment charges
0 -6,261 0 26,082
Total operating expenses
27,834 32,496 32,091 55,122
Operating loss
-25,003 -7,755 -24,548 -51,544
Interest expense related to sale of future revenues
1,072 -464 2,399 2,020
Interest income, net
1,206 1,676 1,831 2,087
Other expense, net
-113 -5 -1 -1,758
Total other income, net
21 2,135 -569 -1,691
Net loss
-24,982 -5,620 -25,117 -53,235
Basic EPS
-0.26 -0.058 -0.28 -0.63
Diluted EPS
-0.26 -0.058 -0.28 -0.63
Basic Average Shares
97,879,343 97,425,969 90,090,397 84,412,200
Diluted Average Shares
97,879,343 97,425,969 90,090,397 84,412,200
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income, net$1,206K (-55.60%↓ Y/Y)Net loss-$24,982K (67.17%↑ Y/Y)Total other income,net$21K (-72.00%↓ Y/Y)Interest expense relatedto sale of future...$1,072K (-51.62%↓ Y/Y)Other expense, net-$113K (73.41%↑ Y/Y)Operating loss-$25,003K (67.17%↑ Y/Y)Collaboration and otherresearch and development...$2,831K (-39.22%↓ Y/Y)Total operatingexpenses$27,834K (-65.56%↓ Y/Y)Research and development$17,600K (-33.82%↓ Y/Y)General andadministrative$10,234K (-23.48%↓ Y/Y)

Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. (EDIT)